Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Neural Regulation01:37

Neural Regulation

34.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
34.6K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

16
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
16
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

13.4K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
13.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-Fat Diet Exacerbates Neuropathology in a Transgenic Mouse Model of Multiple System Atrophy.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Report of the scientific network Holimitox on succinate dehydrogenase inhibitor (SDHI) pesticides: new insights and challenges with an EcoHealth approach-presentations and round tables from the Holimitox day on November 7, 2024.

Environmental science and pollution research international·2026
Same author

Shared and distinct lipid profiles in amygdala from sporadic and GBA-associated Parkinson's diseases.

NPJ Parkinson's disease·2026
Same author

WDR44 drives de novo α-synuclein aggregation at the lysosomal membrane and promotes neuronal dysfunction in Parkinson's Disease.

bioRxiv : the preprint server for biology·2026
Same author

Progress in modelling ATP13A2-linked neurodegeneration.

NPJ Parkinson's disease·2026
Same author

OpenScientist: evaluating an open agentic AI co-scientist to accelerate biomedical discovery.

medRxiv : the preprint server for health sciences·2026
Same journal

Gene Therapy for Amino Acid Decarboxylase Deficiency: Clinical and Imaging Outcomes in a French Cohort.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Alzheimer's Disease Cerebrospinal Fluid Biomarkers Predict Survival in Progressive Supranuclear Palsy.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Hyperhomocysteinemia and Vitamin B Deficiency as Potential Aggravating Factors in Huntington's Disease: A Prospective Monocentric Study.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Longitudinal Dynamics of Polyglutamine-Expanded ATXN3 in Biofluids of Spinocerebellar Ataxia Type 3.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Putamen Structural-Functional Decoupling as an Early-Stage Candidate Imaging Marker for Motor Severity in Spinocerebellar Ataxia Type 3.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Melanopsin-Mediated Post-Illumination Pupillary Response in Idiopathic Rapid Eye Movement (REM) Sleep Behavior Disorder and Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026
See all related articles

Related Experiment Video

Updated: Apr 24, 2026

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model
08:24

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

Published on: November 25, 2022

2.2K

Down-regulating α-synuclein for treating synucleopathies

Mathieu Bourdenx1, Benjamin Dehay, Erwan Bezard

  • 1Institute of Neurodegenerative Diseases, University of Bordeaux, Centre National de la Recherche Scientifique Unité Mixte de Recherche, Bordeaux, France.

Movement Disorders : Official Journal of the Movement Disorder Society
|September 13, 2014
PubMed
Summary

No abstract available in PubMed .

Keywords:
Parkinson's diseasesiRNAtherapeutic strategyα-synuclein

More Related Videos

Recombinant α- β- and γ-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays
09:36

Recombinant α- β- and γ-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays

Published on: August 13, 2017

8.1K
Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
12:01

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein

Published on: May 30, 2015

10.5K

Related Experiment Videos

Last Updated: Apr 24, 2026

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model
08:24

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

Published on: November 25, 2022

2.2K
Recombinant α- β- and γ-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays
09:36

Recombinant α- β- and γ-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays

Published on: August 13, 2017

8.1K
Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
12:01

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein

Published on: May 30, 2015

10.5K